Collaborations

HemoShear works in research collaborations with pharmaceutical and biotech companies to aid them in accelerating and improving the results of their efforts in drug discovery and development. Utilizing our scientific expertise and our proprietary platform technology, we develop human and/or animal cell-based organ and disease systems that enable the study of specific research hypotheses for our customers. HemoShear's scientists work in close collaboration with our customer's scientists to understand their research objectives and needs. We then design and conduct experiments in the appropriate HemoShear surrogate system and analyze the results to provide the customer with unique insights that further their drug discovery and development efforts.

HemoShear works with customers in research collaborations that span single or multiple therapeutic areas. Frequently our collaborations start by working on a single research project for our customer. However, given the broad flexibility and applicability of the HemoShear system, this leads to more extensive, multi-year collaborations across multiple aspects of a drug discovery/development program or programs. We work with customers in a specific research area on either an exclusive or non-exclusive basis.

Shown below are some examples of how the HemoShear technology has been applied to specific programs on behalf of our customers:

• Genome-wide profiling for vascular inflammation and hypertensive disease targets
• Creation of an inflammation surrogate system for target identification & validation
• Validation of a target that plays a key role in vascular wall homeostasis
• Specific cell surface quantification/turnover for a biologics target and computational analyses for "coverage" assessment for atherosclerosis
• Functional assessments of vascular permeability and monocyte adhesion
• Differentiate the hypertensive effects of four compounds
• Validate use of permeability systems to de-risk clinical vascular edema of a specific compound class
• Safety assessment and predictive system for flow-mediated effects of compound and drug-induced vascular injury in a small animal artery system